Syndax Announces Participation in March Investor Conferences

Core Insights - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing innovative cancer therapies [2] - The company has an FDA-approved pipeline that includes Revuforj (revumenib), a menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor [2] - Syndax is committed to advancing cancer care through its clinical trials and innovative treatments [2] Upcoming Events - Syndax's CEO and management team will participate in investor conferences, including the TD Cowen 45th Annual Health Care Conference on March 4, 2025, and the Barclays 27th Annual Global Healthcare Conference on March 13, 2025 [3] - Live webcasts of these events will be available on the company's website, with replays accessible for a limited time [1][3]